Gland Pharma Vice President (Strategy, Investments & Investor Relations) Ankit Gupta tenders resignation
Telangana: Gland Pharma, a generic injectable-focused pharmaceutical company, has informed in a BSE filing that Ankit Gupta, Vice President (Strategy, Investments & Investor Relations) and SMP of the Company has tendered resignation to pursue other interests and opportunities.
"The resignation was accepted and approved by the members of the Nomination and Remuneration Committee of the Board of Directors on December 03, 2024, and he would be relieved from his official duties from the close of business hours on December 31, 2024 and consequently he shall cease to be the SMP of the Company with effect from January 01, 2025," the Company stated.
Ankit joined Gland in 2023. Before joining Gland, Ankit was the Vice President and Head of Corporate Development and Strategy for Strides Pharma Science Limited. Before Strides, Ankit was part of the consulting leadership team for Christensen (now EY Transaction Advisory), a capital market firm based in Mumbai. He also had a stint with other pharmaceutical companies in API and formulations.
Ankit holds an MBA in Finance (Gold Medalist) and has other certifications in corporate finance, private equity, valuations, business leadership, and strategy.
Additionally, Gland Pharma, recently received approval from the United States Food and Drug Administration (USFDA) for Latanoprost Ophthalmic Solution, 0.005% (2.5 mL Fill), a product used for the treatment of high eye pressure/intraocular pressure (IOP) in patients with openangle glaucoma or ocular hypertension.
Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a business-to-business (B2B) model and develops, manufactures, and markets sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.
Read also: USFDA nod to Gland Pharma Latanoprost Ophthalmic Solution
